(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

G00002

(43) International Publication Date
22 August 2002 (22.08.2002)

PCT

(10) International Publication Number
WO 02/064568 A1

(51) International Patent Classification[7]: C07D 213/80, 213/81, 213/82, 521/00, 405/14, 409/14, 401/14, A61K 31/4427, 31/44, A61P 9/00, 19/00

(21) International Application Number: PCT/IB02/00345

(22) International Filing Date: 4 February 2002 (04.02.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/268,781 14 February 2001 (14.02.2001) US

(71) Applicant *(for all designated States except US)*: **WARNER-LAMBERT COMPANY** [US/US]; 201 Tabor Road, Morris Plains, NJ 07950 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BARVIAN, Nicole, Chantel** [US/US]; Pfizer Global Research & Development, Ann Arbor Laboratories, 2800 Plymouth Road, Ann Arbor, MI 48105 (US). **CONNOR, David, Thomas** [GB/US]; Pfizer Global Research & Development, Ann Arbor Laboratories, 2800 Plymouth Road, Ann Arbor, MI 48105 (US). **O'BRIEN, Patrick, Michael** [US/US]; Pfizer Global Research & Development, Ann Arbor Laboratories, 2800 Plymouth Road, Ann Arbor, MI 48105 (US). **ORTWINE, Daniel, Fred** [US/US]; Pfizer Global Research & Development, Ann Arbor Laboratories, 2800 Plymouth Road, Ann Arbor, MI 48105 (US). **PATT, William, Chester** [US/US]; Pfizer Global Research & Development, Ann Arbor Laboratories, 2800 Plymouth Road, Ann Arbor, MI 48105 (US). **SHULER, Kevon, Ray** [US/US]; Pfizer Global Research & Development, Ann Arbor Laboratories, 2800 Plymouth Road, Ann Arbor, MI 48105 (US). **WILSON, Michael, William** [US/US]; Pfizer Global Research & Development, Ann Arbor Laboratories, 2800 Plymouth Road, Ann Arbor, MI 48105 (US).

(74) Agents: **LUMB, J., Trevor** et al.; c/o Simpson, Alison, Urquhart-Dykes & Lord, 30 Welbeck Street, London W1G 8ER (GB).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

162162

WO 02/064568 A1

(54) Title: PYRIDINE MATRIX METALLOPROTEINASE INHIBITORS



(I)

(57) Abstract: Selective MMP-13 inhibitors are pyridine derivatives of the formula (I) or a pharmaceutically acceptable salt thereof, wherein: R^1 and R^2 independently are hydrogen, halo, hydroxy, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_2-C_6 alkenyl, C_2-C_6 alkynyl, NO_2, NR^4R^5, CN, or CF_3; E is independently O or S; A and B independently are OR^4 or NR^4R^5; R^4 and R^5 independently are H, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, $(CH_2)_n$ aryl, $(CH_2)_n$ cycloalkyl, $(CH_2)_n$ heteroaryl, or R^4 and R^5 when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted; n is 0 to 6.